These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 33380864)

  • 1. Consensus recommendations for optimizing biomarker testing to identify and treat advanced
    Cheema PK; Gomes M; Banerji S; Joubert P; Leighl NB; Melosky B; Sheffield BS; Stockley T; Ionescu DN
    Curr Oncol; 2020 Dec; 27(6):321-329. PubMed ID: 33380864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer.
    Lim C; Tsao MS; Le LW; Shepherd FA; Feld R; Burkes RL; Liu G; Kamel-Reid S; Hwang D; Tanguay J; da Cunha Santos G; Leighl NB
    Ann Oncol; 2015 Jul; 26(7):1415-21. PubMed ID: 25922063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-based best practices for
    Stockley T; Souza CA; Cheema PK; Melosky B; Kamel-Reid S; Tsao MS; Spatz A; Karsan A
    Curr Oncol; 2018 Apr; 25(2):163-169. PubMed ID: 29719432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer.
    Ionescu DN; Stockley TL; Banerji S; Couture C; Mather CA; Xu Z; Blais N; Cheema PK; Chu QS; Melosky B; Leighl NB
    Curr Oncol; 2022 Jul; 29(7):4981-4997. PubMed ID: 35877256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
    Pirker R; Herth FJ; Kerr KM; Filipits M; Taron M; Gandara D; Hirsch FR; Grunenwald D; Popper H; Smit E; Dietel M; Marchetti A; Manegold C; Schirmacher P; Thomas M; Rosell R; Cappuzzo F; Stahel R;
    J Thorac Oncol; 2010 Oct; 5(10):1706-13. PubMed ID: 20871269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.
    Keedy VL; Temin S; Somerfield MR; Beasley MB; Johnson DH; McShane LM; Milton DT; Strawn JR; Wakelee HA; Giaccone G
    J Clin Oncol; 2011 May; 29(15):2121-7. PubMed ID: 21482992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
    Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K
    Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia.
    Mitsudomi T; Tan D; Yang JC; Ahn MJ; Batra U; Cho BC; Cornelio G; Lim T; Mok T; Prabhash K; Reungwetwattana T; Ren SX; Singh N; Toyooka S; Wu YL; Yang PC; Yatabe Y
    J Thorac Oncol; 2023 Apr; 18(4):436-446. PubMed ID: 36379356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
    Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J;
    Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
    Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
    Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.
    Ahn MJ; Mendoza MJL; Pavlakis N; Kato T; Soo RA; Kim DW; Liam CK; Hsia TC; Lee CK; Reungwetwattana T; Geater S; Chan OSH; Prasongsook N; Solomon BJ; Nguyen TTH; Kozuki T; Yang JC; Wu YL; Mok TSK; Tan DS; Yatabe Y
    Clin Lung Cancer; 2022 Dec; 23(8):670-685. PubMed ID: 36151006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer.
    Fang S; Wang Z
    Drug Des Devel Ther; 2014; 8():1595-611. PubMed ID: 25302015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
    Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
    Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing.
    Prabhash K; Advani SH; Batra U; Biswas B; Chougule A; Ghosh M; Muddu VK; Sahoo TP; Vaid AK
    Adv Ther; 2019 Apr; 36(4):766-785. PubMed ID: 30864106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biopsy Procedures and Molecular Testing Utilization and Related Costs in Patients with Metastatic Lung Cancer.
    Shinde R; Cao X; Kothari S
    J Manag Care Spec Pharm; 2016 Oct; 22(10):1194-203. PubMed ID: 27668568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP).
    Garrido P; de Castro J; Concha Á; Felip E; Isla D; López-Ríos F; Paz-Ares L; Ramírez J; Sanz J; Gómez JJ
    Clin Transl Oncol; 2012 May; 14(5):338-49. PubMed ID: 22551539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.